Mucinous tumours of the ovary - Primary and metastatic

Journal of Clinical Pathology

Volumn 65, Issue 7, 2012, Pages 577-579

  Heatley, Mark K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EDITORIAL; FROZEN SECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; OVARY CARCINOMA; OVARY METASTASIS; OVARY TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL;

ADENOCARCINOMA, MUCINOUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; OVARY; TUMOR MARKERS, BIOLOGICAL;

EID: 84863589268     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200407     Document Type: Editorial

References (42)

1. Kruse AJ, Slangan B, Dunselinin GA, et al. Neoplastic transformation of endocervicosis into an extramullerian mucinous cystadenocarcinoma. Hum Pathol 2011;42:143-8.
2. Naik J, Seligman J, Perrin T. Mucinous tumours of the ovary.
3. Logani S, Oliva E, Arnell PM, et al. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol 2005;18:19-25. (Pubitemid 40128090)
4. Wilmott F, Rockall A. Radiological manifestations of metastasis to the ovary.
5. Leen S, Singh N. Pathology of primary and metastatic ovarian mucinous neoplasms.
6. McCluggage WG. Immunohistochemistry in the distinction between primary and metastatic ovarian mucinous neoplasms.
7. Holmes MV, Casas JP, Hingorani AD. Putting genomics into practice. BMJ 2011;343:4953.
8. Heatley MK. Immunohistochemical biomarkers of value in distinguishing primary ovarian carcinoma form gastric carcinoma: a systematic review with statistical metaanalysis. Histopathology 2008;52:267-77.
9. Bacchi CE, Gown AM. Distribution and pattern of expression of villin, a gastrointestinal-associated cytoskeletal protein, in human carcinomas: a study employing paraffin-embedded tissue. Lab Invest 1991;64:418-24.
10. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 2002;117:944-51. (Pubitemid 34564352)
11. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol 2000;13:962-72.
12. Kim MJ. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J Korean Med Sci 2005;20:643-8.
13. Lagendijk JH, Mullink H, van Diest PJ, et al. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 1999;52:283-90. (Pubitemid 29161492)
14. Porcell AL, DeYoung BR, Proca DM, et al. Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol 2000;13:773-8. (Pubitemid 30470167)
15. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem Mol Morphol 1995;3:99-107.
16. Wauters CC, Smedts F, Gerrits LG, et al. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol 1995;26:852-5.
17. Moll R, Lowe A, Laufer J, et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol 1992;140:427-47.
18. Brown RW, Campagna LB, Dunn JK, et al. Immunohistochemical identification of tumor markers in metastatic adenocarcinoma. A diagnostic adjunct in the determination of primary site. Am J Clin Pathol 1997;107:12-19. (Pubitemid 27104630)
19. Goldenberg DM, Sharkey RM, Primus FJ. Immunocytochemical detection of carcinoembryonic antigen in conventional histopathology specimens. Cancer 1978;42:1546-53. (Pubitemid 9038290)
20. Pavelic ZP, Pavelic L, Pavelic K, et al. Utility of anti-carcinoembryonic antigen monoclonal antibodies for differentiating ovarian adenocarcinomas from gastrointestinal metastasis to the ovary. Gynecol Oncol 1991;40:112-17.
21. Sheahan K, O'Brien MJ, Burke B, et al. Differential reactivities of carcinoembryonic antigen (CEA) and CEA-related monoclonal and polyclonal antibodies in common epithelial malignancies. Am J Clin Pathol 1990;94:157-64. (Pubitemid 20229562)
22. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005;29:1482-9. (Pubitemid 41513298)
23. Kaimaktchiev V, Terracciano L, Tornillo L, et al. The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol 2004;17:1392-9. (Pubitemid 39472995)
24. Moskaluk CA, Zhang H, Powell SM, et al. CDX2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol 2003;16:913-19. (Pubitemid 37152021)
25. Werling RW, Hadi Y, Bacchi CE, et al. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin. An immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 2003;27:303-10. (Pubitemid 36245795)
26. Kanner WA, Galgano MT, Stoler MH, et al. Distinguishing breast carcinoma from Müllerian serous carcinoma with mammaglobin and mesothelin. Int J Gynecol Pathol 2008;27:491-5.
27. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol 2008;32:1566-71.
28. Moll R, Robine S, Dudouet B, et al. Villin: a cytoskeletal protein and a differentiation marker expressed in some human adenocarcinomas. Virchows Arch B Cell Pathol Incl Mol Pathol 1987;54:155-69. (Pubitemid 17164663)
29. Hanski C, Hofmeier M, Schmitt-Gräff A, et al. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol 1997;1824:385-91.
30. Ho SB, Niehans GA, Lyftogt C, et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51. (Pubitemid 23059449)
31. Heatley MK. A systematic review of papers examining the utility of intraoperative frozen section in predicting the final diagnosis of ovarian lesions. Int J Gynecol Pathol. In press.
32. Fanfani F, Zannoni GF, Fagotti A, et al. Importance of a specialized pathologist for the examination of frozen sections of adnexal masses. Int J Gynecol Cancer 2007;17:1034-9. (Pubitemid 47414825)
33. Ilvan S, Ramazanoglu R, Ulker Akyildiz E, et al. The accuracy of frozen section (intraoperative consultation) in the diagnosis of ovarian masses. Gynecol Oncol 2005;97:395-9. (Pubitemid 40614880)
34. Kokka F, Singh N, Reynolds K, et al. The accuracy of frozen section diagnosis in apparent early ovarian cancer - results from a UK centre. Histopathology 2009;55:756-8.
35. Naik R, Cross P, Lopes A, et al. "True" versus "apparent" stage I epithelial ovarian cancer: value of frozen section analysis. Int J Gynecol Cancer 2006;16 Suppl 1:41-6.
36. Stewart CJ, Brennan BA, Hammond IG, et al. Accuracy of frozen section in distinguishing primary ovarian neoplasia from tumors metastatic to the ovary. Int J Gynecol Pathol 2005;24:356-62. (Pubitemid 41368289)
37. Stewart CJ, Brennan BA, Koay E, et al. Value of cytology in the intraoperative assessment of ovarian tumors: a review of 402 cases and comparison with frozen section diagnosis. Cancer Cytopathol 2010;118:127-36.
38. Suprasert P, Khunamornpong S, Phusong A, et al. Accuracy of intra-operative frozen sections in the diagnosis of ovarian masses. Asian Pac J Cancer Prev 2008;9:737-40.
39. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 2005;11:3766-72. (Pubitemid 40685594)
40. Heatley MK. Immunohistochemical and functional biomarkers of value in female genital tract lesions, a systematic review with statistical meta analysis. Int J Gynecol Pathol 2007;26:177-9. (Pubitemid 46573215)
41. Liu F, Fan D, Qi J, et al. Co-expression of cytokeratin 8 and breast cancer resistance protein indicates a multifactorial drug-resistance phenotype in human breast cancer cell line. Life Sci 2008;83:496-501.
42. Drake P, Griffiths GJ, Shaw L, et al. Application of high-content analysis to the study of post-translational modification of the cytoskeleton. J Proteome Res 2009;8:28-34.